AGP Executive Report
Last update: 9 hours agoHealthcare Policy (France): France will stop full refunds for “low medical benefit” medicines for long-term illness (ALD) patients from Oct. 1, cutting reimbursement from 100% to the usual 15% for about 171 products, including Gaviscon, Spasfon/Météospasmyl, Dexeryl, Tanakan, Bétadine, Zovirax/aciclovir cream, and Valium—raising costs for people who rely on daily treatments. Public Health Tech: A study suggests drone-delivered defibrillators could reduce delays in treating cardiac arrests, potentially improving survival. Medical Innovation (EU): The European Commission cleared NEZGLYAL® (leriglitazone), the first pharmacological treatment for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease. Injury Update (France sports, health angle): Kylian Mbappé left France’s camp with a hyperextended left knee tendon injury after scoring vs Turkey, with Real Madrid awaiting further medical details. Safety Outdoors (France): A hiker in the French Pyrenees was airlifted after an asp viper bite and received antivenom.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
